HK1049280A1 - 結晶狀細胞保護劑組合物組及其預備與使用的方法 - Google Patents

結晶狀細胞保護劑組合物組及其預備與使用的方法

Info

Publication number
HK1049280A1
HK1049280A1 HK03100668.8A HK03100668A HK1049280A1 HK 1049280 A1 HK1049280 A1 HK 1049280A1 HK 03100668 A HK03100668 A HK 03100668A HK 1049280 A1 HK1049280 A1 HK 1049280A1
Authority
HK
Hong Kong
Prior art keywords
preparation
methods
same
crystalline amifostine
compositions
Prior art date
Application number
HK03100668.8A
Other languages
English (en)
Inventor
E Kennedy Paul
A Rajewski Roger
M Baldoni John
Original Assignee
Medimmune Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25447813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1049280(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Oncology Inc filed Critical Medimmune Oncology Inc
Publication of HK1049280A1 publication Critical patent/HK1049280A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
HK03100668.8A 1992-07-31 2003-01-24 結晶狀細胞保護劑組合物組及其預備與使用的方法 HK1049280A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92292992A 1992-07-31 1992-07-31
US08/099,298 US5424471A (en) 1992-07-31 1993-07-29 Crystalline amifostine compositions and methods of the preparation and use of same

Publications (1)

Publication Number Publication Date
HK1049280A1 true HK1049280A1 (zh) 2003-05-09

Family

ID=25447813

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100668.8A HK1049280A1 (zh) 1992-07-31 2003-01-24 結晶狀細胞保護劑組合物組及其預備與使用的方法

Country Status (8)

Country Link
US (1) US5424471A (zh)
EP (2) EP1243272A3 (zh)
KR (1) KR100297613B1 (zh)
FI (1) FI117924B (zh)
HK (1) HK1049280A1 (zh)
MY (1) MY110631A (zh)
WO (1) WO1994003179A1 (zh)
ZA (1) ZA935532B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
PT2130554E (pt) * 1999-02-22 2012-11-19 Univ Connecticut Formulações de factor viii isentas de albumina
DE60118172T2 (de) * 2000-04-26 2007-03-08 Oregon Health Sciences University, Portland Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
DE10043170C2 (de) * 2000-09-01 2002-10-24 Klinge Co Chem Pharm Fab Amifostin-Monohydrat und Verfahren zu seiner Herstellung
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
US7629333B2 (en) * 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
SE522981C2 (sv) * 2002-07-01 2004-03-23 Nobel Biocare Ab Anordning och metod för att bibehålla nybensbildande effekt hos tillväxtstimulerande substanser vid implantatprodukt
US7604967B2 (en) * 2003-03-19 2009-10-20 The Trustees Of Dartmouth College Lignin-blocking treatment of biomass and uses thereof
WO2005048993A2 (en) * 2003-11-14 2005-06-02 Alza Corporation Minimization of drug oxidation in drug irradiated excipients formulations
US20050187608A1 (en) * 2004-02-24 2005-08-25 O'hara Michael D. Radioprotective compound coating for medical devices
BRPI0509117A (pt) * 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
EP2377554A1 (en) * 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
TW200716504A (en) * 2005-10-18 2007-05-01 jin-zhi Ye The orthopaedic implant products with controllable dissolving rate for biomedical use and the manufacturing method thereof
WO2007047315A1 (en) * 2005-10-20 2007-04-26 Albemarle Corporation Amifostine dihydrate crystalline composition
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007096901A1 (en) * 2006-02-24 2007-08-30 Natco Pharma Limited Novel dihydrate form of amifostine and process for its preparation
US20090239817A1 (en) * 2006-04-17 2009-09-24 Goverment Of The United States Of America, As Represented By The Secretary, Dept Of Health Organic thiophosphate antiretroviral agents
US9585849B2 (en) * 2006-04-17 2017-03-07 The Burlington Hc Research Group, Inc. Broad spectrum antiviral and methods of use
WO2008060441A2 (en) * 2006-11-09 2008-05-22 Scidose Llc Stable amifostine liquid concentrate
US20100168018A1 (en) 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
JPS544672A (en) * 1977-06-10 1979-01-13 Taiyo Shokai Co Ltd Method and device for making material band for gusset pouch
JPS6041676B2 (ja) 1977-09-21 1985-09-18 山之内製薬株式会社 Ｓ−２−（３−アミノプロピルアミノ）エチルジハイドロジエンホスホロチオエ−ト１水和結晶の新規製法
US4424216A (en) * 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
DD289448A7 (de) 1982-07-29 1991-05-02 Amt Fuer Atomsicherheit Und Strahlenschutz,De Verfahren zur herstellung von s-[2-(3-amino-propylamino)ethyl]-dihydrogenthiophosphat
DD289449A7 (de) 1983-07-29 1991-05-02 Amt Fuer Atomsicherheit Und Strahlenschutz,De Verfahren zur herstellung von s-[2-(3-amino-propylamino)ethyl]-dihydrogenthiophosphat
CA1265052A (en) 1984-08-08 1990-01-30 Stanley J. Sarnoff Absorption enhancing agents
AU638251B2 (en) 1989-05-24 1993-06-24 U.S. Bioscience, Inc. Method for protection from azt side effects and toxicity

Also Published As

Publication number Publication date
FI950420A (fi) 1995-03-31
FI950420A0 (fi) 1995-01-31
ZA935532B (en) 1994-02-24
EP1764103A2 (en) 2007-03-21
WO1994003179A1 (en) 1994-02-17
KR950702424A (ko) 1995-07-29
EP1243272A3 (en) 2003-01-22
FI117924B (fi) 2007-04-30
US5424471A (en) 1995-06-13
EP1243272A2 (en) 2002-09-25
EP1764103A3 (en) 2011-08-24
MY110631A (en) 1998-09-30
KR100297613B1 (ko) 2001-10-24

Similar Documents

Publication Publication Date Title
ZA935532B (en) Crystalline amifostine compositions and methods for the preparation and use of same
ZA931935B (en) Preparation of substituted guanidines
EP0707480A4 (en) ANTINEOPLASTIC COMPOSITIONS AND METHOD FOR THEIR USE
IL108142A0 (en) Aminoureaformaldehyde fertilizer composition and its preparation
IL105939A0 (en) Herbicidal compounds and compositions
AU2065992A (en) Herbicidal compositions and methods of preparing and using the same
GB9215551D0 (en) New compositions of matter
HRP931429B1 (en) Process for the preparation of amlodipin benzensulphonate
EP0585168A3 (en) Composition and methods for the generation of bone
GB9108043D0 (en) Method for the formation of liposomes and compositions for use therein
GB2264941B (en) Preparation of granular compositions
AU5847694A (en) Chlorofluoroether compositions and preparation thereof
GB9225923D0 (en) New compositions of matter
GB9222985D0 (en) Use of the tarchonanthus camphoratus
ZA939155B (en) Substituted N-hydroxycinnamamides processes for their preparation compositions containing them and their use
GB9220143D0 (en) Compounds and compositions
GB9200519D0 (en) Composition of matter
GB9200689D0 (en) New compositions of matter
GB9220088D0 (en) Compounds and compositions
ZA921040B (en) Process for the preparation of 4-alkylsulfonyl-1-alkyl-2-chlorobenzenes and similar compounds
EP0564212A3 (en) Process for the preparation of arylethylamines and substituted arylethylamines
HU9601041D0 (en) Method for the preparation of quinolone-containing oral compositions
EP0564213A3 (en) Process for the preparation of arylethylamines and substituted arylethylamines
HU900600D0 (en) Herbicide compositions containing substituted sulfonyl-carbamide-derivatives and process for preparation of the agents
EP0553954A3 (en) Preparation of tetramethyldiamino-polyoxyethylenes